兴科蓉医药发布中期业绩 股东应占溢利2438.9万元 同比增加2.17%

Group 1 - The company, Xingke Rong Pharmaceutical (06833), reported revenue of 1.196 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 21.68% [1] - The profit attributable to the company's owners was 24.389 million RMB, showing a year-on-year increase of 2.17% [1] - The basic earnings per share were 0.012 RMB [1]